Cardiol Therapeutics Inc. (CRDL)

NCM – Real Time Price. Currency in USD

1.35

+0.01 (1.12%)

At close: May 12, 2026, 4:00 PM EDT

1.33

-0.02 (-1.48%)

After-hours: May 12, 2026, 7:54 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Cardiol Therapeutics Inc. (CRDL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Videos

No Data

Press releases

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Search stocks

Cardiol Therapeutics Inc. (CRDL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Videos

No Data

Press releases

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Cardiol Therapeutics Announces Year-End 2025 Update on Operations